Literature DB >> 8526739

Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome.

F Sato1, Y Hagiwara, Y Kawase.   

Abstract

Consumption of certain product lots of L-tryptophan (LT) has been reported to be epidemiologically associated with an outbreak of eosinophilia-myalgia syndrome (EMS) in the United States. Since the production lots were found to contain 3-phenylamino alanine (PAA) as an impurity, its effects were studied by administering the substance orally by gavage to 5-week-old Sprague-Dawley rats. Groups of animals were given PAA for 13 consecutive weeks at dose levels of 1, 10 and 100 mg/kg per day. The animals were killed at 4 or 8 weeks. Hematological and blood biochemical tests were performed and detailed histopathological observations were made. No significant abnormalities were observed in the test animals and in particular no EMS-like conditions. A brief summary of other animal studies using several species of rats and mice performed in our laboratory since 1989 on various LT related substances is also presented. No EMS-like effects were observed in these studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8526739     DOI: 10.1007/s002040050197

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  18 in total

1.  3-anilino-L-alanine, structural determination of UV-5, a contaminant in EMS-associated L-tryptophan samples.

Authors:  Y Goda; J Suzuki; T Maitani; K Yoshihira; M Takeda; M Uchiyama
Journal:  Chem Pharm Bull (Tokyo)       Date:  1992-08       Impact factor: 1.645

2.  L-tryptophan-associated eosinophilic fasciitis prior to the 1989 eosinophilia-myalgia syndrome outbreak.

Authors:  J R Hibbs; B Mittleman; P Hill; T A Medsger
Journal:  Arthritis Rheum       Date:  1992-03

3.  Eosinophilia-myalgia syndrome. Results of national surveillance.

Authors:  L A Swygert; E F Maes; L E Sewell; L Miller; H Falk; E M Kilbourne
Journal:  JAMA       Date:  1990-10-03       Impact factor: 56.272

4.  A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).

Authors:  R M Silver; A Ludwicka; M Hampton; T Ohba; S A Bingel; T Smith; R A Harley; J Maize; M P Heyes
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

5.  Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.

Authors:  R M Philen; R H Hill; W D Flanders; S P Caudill; L Needham; L Sewell; E J Sampson; H Falk; E M Kilbourne
Journal:  Am J Epidemiol       Date:  1993-08-01       Impact factor: 4.897

6.  Magnesium deficiency in the eosinophilia-myalgia syndrome. Report of clinical and biochemical improvement with repletion.

Authors:  D J Clauw; K Ward; B Wilson; P Katz; S S Rajan
Journal:  Arthritis Rheum       Date:  1994-09

7.  L-tryptophan and the eosinophilia-myalgia syndrome: pathologic findings in eight patients.

Authors:  M K Herrick; Y Chang; D S Horoupian; C M Lombard; B T Adornato
Journal:  Hum Pathol       Date:  1991-01       Impact factor: 3.466

8.  3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?

Authors:  A N Mayeno; E A Belongia; F Lin; S K Lundy; G J Gleich
Journal:  Mayo Clin Proc       Date:  1992-12       Impact factor: 7.616

9.  Tryptophan-induced lung disease: an immunophenotypic, immunofluorescent, and electron microscopic study.

Authors:  H D Tazelaar; J L Myers; J G Strickler; T V Colby; J Duffy
Journal:  Mod Pathol       Date:  1993-01       Impact factor: 7.842

10.  An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use.

Authors:  E A Belongia; C W Hedberg; G J Gleich; K E White; A N Mayeno; D A Loegering; S L Dunnette; P L Pirie; K L MacDonald; M T Osterholm
Journal:  N Engl J Med       Date:  1990-08-09       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.